Cancer incidence after immunosuppressive treatment following kidney transplantation
Introduction
Renal transplant is the treatment of end-stage renal failure that provides the best quality of life to the patient. However, the immunosuppressant treatment necessary for long-term renal transplant functioning has a series of short and long-term side effects, such as infections, increased cardiovascular risk and neoplastic diseases, which can be life-threatening for the patient.
De novo cancer is a major complication of renal transplant that causes significant short and long-term mortality. It accounts for 20% of the exitus of renal transplant patients every year and accounts for 30% of the death causes of the renal transplant recipients with a follow-up greater than 20 years [1].
The main information on cancer in the renal transplanted patient comes from the Cincinnati Transplant Tumor Registry (CTTR), elaborated by Penn since the 1970 [2], [3], [4], [5], from the Nordic Renal Transplant Registry (NRTR) that includes cases from Scandinavian countries [6], [7], [8], [9] and the Australian and New Zealand Transplant Registry (ANTR) [10], [11], [12]. In addition to these registries, there are many studies from a single center or regional registries that supply very valid information. However, this information does not always agree with that expressed in the large registries since they take ethnic and environment characteristics of each region into account.
Immunosuppression is the main risk factor for the development of short and long-term neoplasms after transplantation of any organ. However, some authors do not admit this etiopathogenic association for all the cancer types that the renal transplant recipients may develop [13]. Each organ has some epidemiological characteristics for development of post-transplant neoplasms. Specifically in the renal transplant, it is known that neoplasms are more frequent in the patient receiving dialysis than in the age-matched general population [5], [14]. On the one hand, in some patients, cancer is the cause of renal failure as, for example, patients with multiple myeloma or with surgically treated renal or urinary tract neoplasms. On the other hand, analgesic nephropathy, a known cause of end stage renal disease, is associated with a greater risk of renal cancer [15]. And finally, patients who remain on dialysis for a long time frequently acquire a cystic disease in their non-functioning native kidneys, that is associated with a higher incidence of renal carcinoma [14], [16].
Furthermore, renal donor and recipient characteristics have been changing in recent years. Renal transplant recipient and cadaveric donor age is increasing [17]; thus, cancer prevalence in the older recipients as well as danger of transmission of unnoticed neoplasm from older donors will be higher.
We are going to divide this exposition into three classical sections to describe the epidemiology of neoplasms in renal transplant: (1) renal transplant candidates with cancer; (2) tumors transmitted from the organ donor; (3) de novo neoplasms in the renal transplant recipient. In this latter section, we will distinguish early appearing and late appearing neoplasms.
Section snippets
Renal transplant candidates with neoplasm
In a retrospective study, Penn [18], [19] observed that after renal transplant, recurrence of previously existing and treated neoplasms in the recipients was 22%. A total of 54% of the recurrences were cancers treated in the two pre-transplant years, 33% in those treated 2–5 years before and only 13% in those treated more than 5 years before.
Table 1, Table 2 summarize the recurrence incidence of pre-existing tumors in the recipient before the renal transplant and waiting times recommended
Donor transmitted cancer
Any background of malignant neoplasm in donors should be an absolute contraindication to the donation of their organs. However, the scarcity of organs for transplant and the long waiting lists for transplant have led to the consideration of donors with central nervous system (CNS) cancers that only rarely metastasize as well as donors with background of cured neoplasm and donors with in situ cancers discovered when the organs are procured. Some of these organs have been transplanted after the
De novo neoplasms after renal transplant
According to the CTTR, the most prevalent de novo neoplasms in organ transplant recipients are skin cancers and post-transplant lymphoproliferative disease (PTLD). Cutaneous neoplasms predominate in the renal recipient on the contrary to in the non-renal organ recipient in which the most prevalent neoplasms are the PTLD [4] (Table 8). This different distribution of the de novo neoplasms in renal and non-renal transplant recipients may be explained by the greater follow-up time and the lower
Dr. Amado Andrés carried out his medical studies in the “Autónoma” University of Madrid, graduating in 1981. Later, he studied the nephrology speciality in the Hospital 12 de Octubre of Madrid and obtained his PhD in Medicine in 1992. Since 1988, he has been working in renal transplant area in the nephrology department of the Hospital 12 de Octubre. Since 1989, he has been the general transplant coordinator in the Hospital 12 de Octubre. He has published more than 200 articles in journals and
References (98)
Posttransplant malignancies
Transplant Proc
(1999)- et al.
Cancer risk in patients on dialysis and after renal transplantation
Lancet
(2000) Patterns of malignancies following renal transplantation
Transplant Proc
(1999)- et al.
Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation
Transplant Proc
(1997) - et al.
Cancer in patients on dialysis for end-stage renal disease: an international collaborative study
Lancet
(1999) - et al.
Results of kidney transplantation in recipients over 70 years of age: experience at a single center
Transplant Proc
(2003) - et al.
Recurrence of cancer after renal transplantation
Transplant Proc
(2001) - et al.
Screening for prostate, breast and colorectal cancer in renal transplant recipients
Am J Transplant
(2003) - et al.
Interferon-alpha and the cure of metastasis of a malignant meningioma in a kidney allograft recipient: a case report
Transplant Proc
(1997) - et al.
Transmission of glioblastoma multiforme through liver transplantation
Lancet
(July 4, 1998)
Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report
Transplant Proc
Prostate-specific antigen in the assessment of organ donors
Transplant Proc
Evaluation and selection of potential live kidney donors
J Urol
Cancer after kidney transplantation in the United States
Am J Transplant
Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation
Lancet
Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period
Transplant Proc
Malignancies in patients under long-term immunosuppression after kidney transplantation
Transplant Proc
Clinical study of malignancies after renal transplantation and impact of routine screening for early detection: a single-center experience
Transplant Proc
Risk of neoplasia in renal transplant patients
Lancet
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens
Lancet
Outcome of renal transplantation in patients with a functioning graft for 20 years or more
J Urol
Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium
Am J Transplant
Lymphoproliferative disease in children
Transplant Proc
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients
Lancet
Lymphomas after solid organ transplantation: a collaborative transplant study report
Am J Transplant
Cancer risk associated with ATG/OKT3 in renal transplantation
Transplant Proc
Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients
Am J Transplant
Cancers in renal transplant recipients
Adv Ren Replace Ther
Israel Penn International Transplant Tumor Registry. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry
Transplant Proc
Hepatocellular carcinoma after kidney transplantation
Transplant Proc
Rapamycin is an effective inhibitor of human renal cancer metastasis
Kidney Int
Twenty and 25 years survival after cadaveric renal transplantation
Transplant Proc
Post-transplant malignancy: the role of immunosuppression
Drug Saf
Occurrence of cancers in immunosuppressed organ transplant recipients
Clin Transplant
Effect of two cyclosporin regimens on cancer frequency in kidney-graft recipients
Lancet
De novo cancers complicating renal transplantation: experience in the Nordic countries
Ann Transplant
Cancer risk after renal transplantation in the Nordic countries, 1964–1986
Int J Cancer
Development of malignancy following renal transplantation in Australia and New Zealand
Transplant Proc
Malignancies after renal transplantation: the EDTA-ERA registry experience. European Dialysis and Transplantation Association-European Renal Association
Nephrol Dial Transplant
Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand
J Am Soc Nephrol
Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis
J Clin Pathol
Evaluation of transplant candidates with pre-existing malignancies
Ann Transplant
The effect of immunosuppression on pre-existing cancers
Transplantation
European Best Practice Guidelines for Renal Transplantation (part 1)
Nephrol Dial Transplant
The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians
J Am Soc Nephrol
Screening for solid organ malignancies prior to heart transplantation
Transplant Proc
Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation
J Am Soc Nephrol
Transmission of cancer from organ donors
Ann Transplant
Cited by (112)
Glucose as a Risk Factor for Periodontitis in Kidney Transplantation Patients
2023, Transplantation ProceedingsDrug-Induced Malignancy
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionHLA alleles in renal transplant recipients with nonmelanoma skin cancer in southeastern Brazil
2019, Anais Brasileiros de DermatologiaRobot-Assisted Radical Prostatectomy in a Post−Kidney Transplant Patient: An Initial Case Report in China
2018, Transplantation ProceedingsUrologic malignancies in renal transplant candidates and recipients
2016, Progres en UrologieInduction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab
2015, Journal of Heart and Lung Transplantation
Dr. Amado Andrés carried out his medical studies in the “Autónoma” University of Madrid, graduating in 1981. Later, he studied the nephrology speciality in the Hospital 12 de Octubre of Madrid and obtained his PhD in Medicine in 1992. Since 1988, he has been working in renal transplant area in the nephrology department of the Hospital 12 de Octubre. Since 1989, he has been the general transplant coordinator in the Hospital 12 de Octubre. He has published more than 200 articles in journals and books on his speciality. His research lines are focused on the study of expanded donor pool, older donors kidney transplant and management of several immunosuppressive therapies. He has directed several research projects on these issues as well as some doctorate thesis.